Back to search results

Perampanel for Seizure Prevention After Cardiac Arrest

This study is testing a drug called perampanel to see if it can safely prevent seizures (status epilepticus) in patients who have survived a heart attack (cardiac arrest). After a cardiac arrest, brain injury is common, and seizures can occur in many patients. Perampanel works by blocking a specific brain chemical receptor (AMPA glutamate receptor) that plays a role in seizures. Researchers want to find out if perampanel is safe and can help prevent these seizures. You might be able to join if you are at least 18 years old, had a cardiac arrest outside the hospital, are in a coma, and were revived within 45 minutes. The study will look at how safe perampanel is and if there are any serious side effects within 7 days.

Study design
This is a pilot randomized, placebo-controlled study, meaning some participants will receive perampanel and others will receive a placebo (an inactive substance). The study plans to enroll 52 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The safety and tolerability of perampanel, as well as adverse events, will be measured at 7 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06401707

PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest

Recruiting
PHASE2Ages 18+InterventionalPrevention
University of California, San Francisco
~52 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:PerampanelPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and tolerability of perampanel
Measured over 7 days
+1 more outcome measured

Conditions

Heart Arrest
Seizures
Status Epilepticus

Explore related trials

Cardiac ArrestStatus Epilepticus

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Edilberto Amorim, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

Edilberto Amorim, MD
[email protected]
628-206-3203
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years old
Non-traumatic, out-of-hospital cardiac arrest
Comatose on admission - defined as not following commands
Return of spontaneous circulation (ROSC) within less than 45 minutes from the time of cardiac arrest (defined as the time of 911 or EMS (emergency medical services) witnessed arrest)
Admission to the intensive care unit at Zuckerberg San Francisco General Hospital

Exclusion

Acute cerebral hemorrhage or infarction
Pregnancy
Prisoner
Severe kidney function impairment with creatinine clearance inferior to 30 ml/min
Severe liver impairment with liver function tests five times above the upper limit of normal
Electrographic or electroclinical seizures diagnosis using American Clinical Neurophysiology criteria confirmed by an epileptologist after cardiac arrest

What this trial measures

  • Safety and tolerability of perampanel7 days

    percentage of participants who are able to complete the 5-day course of perampanel or placebo.

  • Adverse and Serious Adverse Events7 days

    percentage of participants with treatment-related adverse and serious adverse events in perampanel or placebo arms.